Nicox Announces Approval of ZERVIATE in China

On September 18, 2024, Nicox SA announced that its Chinese partner, Ocumension Therapeutics, has received approval for the commercialization of ZERVIATE® in China. ZERVIATE® (cetirizine ophthalmic solution) is designed to treat ocular itching associated with allergic conjunctivitis.

This approval is expected to bolster Nicox's revenue through royalties and commercial milestones. Ocumension projects annual peak sales of over $100 million within seven years. ZERVIATE is already marketed in the U.S. by Harrow, Inc.

Ocumension will manufacture ZERVIATE in its new facility in Suzhou, China, and promote it through its extensive network. The Chinese market for allergic conjunctivitis products is anticipated to reach nearly $500 million by 2030.

Nicox holds exclusive licensing rights for ZERVIATE in Chinese and most Southeast Asian markets, with potential sales milestones up to $17.2 million and royalties ranging from 5% to 9% of net sales.